Dr. Goodenow Announces Selection of OAR Deputy Director

Maureen M. Goodenow, Ph.D.Dr. Peter Kim, M.D.
Deputy Director, Office of AIDS Research



“I am delighted to announce the appointment of Peter Kim, M.D., as the Deputy Director, of the Office of AIDS Research (OAR). Dr. Kim is a physician with board certifications in the practice of Internal Medicine and Infectious Diseases. He has been involved in the HIV research field for more than eight years.

Currently, Dr. Kim is serving as the Deputy Director for the Therapeutic Research Program in the Division of AIDS (DAIDS), National Institute of Allergies and Infectious Diseases (NIAID). In that role, he oversees a broad portfolio of grants and contracts related to the therapy and diagnosis of HIV and HIV-associated conditions. He also oversees the safety and performance of clinical trials performed under the auspices of the Therapeutic Research Program, DAIDS. Furthermore, he is an active volunteer physician, providing clinical care for HIV and TB infected patients at the Montgomery County TB Clinic, in Maryland.

In addition to his medical background, Dr. Kim has experience in management and community involvement. He is a founding member of the TB Drug Resistance Consortium; Chair, Pediatric TB Research Team; Advisory Board Member, TB Modeling and Analysis Consortium; and Co-Chaired the Diagnostic Working Group, Federal TB Task Force. He has published 23 papers in peer-reviewed literature, all pertaining to HIV/AIDS.

Dr. Kim earned his Bachelor of Arts in Public Health from Johns Hopkins University before completing his Doctor of Medicine at the University of Maryland, School of Medicine. He completed both his internship and residency in Internal Medicine at the Washington Hospital Center, and was the Chief Medical Resident. In addition, Dr. Kim completed his Fellowship in Infectious Diseases at the Washington Hospital Center.

Dr. Kim’s vision for OAR aligns with my own. He is interested in research to inform strategies for improved health outcomes for those with co-infections and co-morbidities, as well as a diversified research portfolio that is well coordinated to allow maximum return on investment and to ensure that the potential of our current success is fully realized. He is an outstanding addition to our team.

Dr. Kim officially started on January 9, 2017, but over the following two months he will be completing responsibilities at NIAID while he is transitioning to his new role in OAR. By late February, he will be in our office fulltime. We look forward to Dr. Kim’s contribution to the important mission of our office!”

This page last reviewed on September 25, 2017